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Abstract Recent sequencing studies have extensively explored the somatic alterations present in 
the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, 
the origins and impact of cancer-associated mutations in mtDNA are unclear. In this study, we 
analyzed somatic alterations in mtDNA from 1675 tumors. We identified 1907 somatic substitutions, 
which exhibited dramatic replicative strand bias, predominantly C > T and A > G on the mitochondrial 
heavy strand. This strand-asymmetric signature differs from those found in nuclear cancer genomes 
but matches the inferred germline process shaping primate mtDNA sequence content. A number of 
mtDNA mutations showed considerable heterogeneity across tumor types. Missense mutations were 
selectively neutral and often gradually drifted towards homoplasmy over time. In contrast, mutations 
resulting in protein truncation undergo negative selection and were almost exclusively heteroplasmic. 
Our findings indicate that the endogenous mutational mechanism has far greater impact than any 
other external mutagens in mitochondria and is fundamentally linked to mtDNA replication.
DOI: 10.7554/eLife.02935.001
Introduction
All cancers result from somatic mutations in their genomes. Beyond the ∼3200 Mb of nuclear genomic DNA, 
human cells have hundreds to thousands of mitochondria present in every cell, each carrying one or a few 
copies of the 16,569 bp circular mitochondrial genomes (Smeitink et al., 2001; Legros et al., 2004; 
eLife digest The DNA in a cell's nucleus must be copied faithfully, and divided equally, when a 
cell divides to produce two new cells. Mistakes—or mutations—are sometimes made during the 
copying process, and mutations can also be introduced by exposing DNA to damaging agents 
known as mutagens, such as UV light or cigarette smoke. These mutations are then maintained in all 
of the descendants of the cell. Most of these mutations have no impact on the cell's characteristics 
(‘passenger mutations’). However, ‘driver mutations’ that allow cells to divide uncontrollably and 
spread to other body sites can lead to cancer.
Mitochondria are cellular compartments that are responsible for generating the energy a cell 
needs to survive and are also responsible for initiating programmed cell death. Mitochondria contain 
their own DNA—entirely separate from that in the nucleus of the cell—that encodes the proteins 
most essential for energy production. Mitochondrial DNA molecules are frequently exposed to 
damaging molecules called reactive oxygen species that are produced by the mitochondria. 
Therefore, these reactive oxygen species have been thought to be one of the most important causes 
of mitochondrial DNA mutations. In addition, because cancer cells produce energy differently to 
normal cells, mutations in the mitochondrial DNA that change the ability of the mitochondria to 
produce energy have been conventionally thought to help normal cells to become cancerous. 
However, conclusive evidence for a link between cancer and mitochondrial DNA mutations is lacking.
Ju et al. examined the mitochondrial DNA sequences taken from 1675 cancer biopsies from over 
thirty different types of cancer and compared these to normal tissue from the same patients. This 
revealed 1907 mutations in the mitochondrial DNA taken from the cancer cells. The pattern of the 
mutations suggests that the majority of the mutations are not introduced from reactive oxygen 
species, but from the errors the mitochondria themselves make in the process of duplicating their 
DNA when a cell divides. Unexpectedly, known mutagens, such as cigarette smoke or UV light, had 
a negligible effect on mitochondrial DNA mutations.
Contrary to conventional wisdom, Ju et al. found no evidence that the mitochondrial DNA 
mutations help cancer to develop or spread. Instead, like passenger mutations found in the DNA in 
the cell nucleus, most mitochondrial genome mutations have no discernible effect. However, Ju et 
al. revealed that DNA mutations that damage normal mitochondrial activity are less likely to be 
maintained in cancer cells. Presumably, mitochondria containing these proteins produce less energy, 
and so a cell containing too many of these mutations will find it harder to survive. This shows that 
having enough correctly functioning mitochondria is essential for even cancer cells to thrive.
DOI: 10.7554/eLife.02935.002
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Koppenol et al., 2011). In addition to their role in cellular energy balance through oxidative phospho-
rylation, mitochondria are involved in many essential cellular functions including modulation of oxidation–
reduction status, contribution to cytosolic biosynthetic precursors, and initiation of apoptosis. 
Mitochondria in eukaryotic cells evolved by endosymbiosis from a free-living α-proteobacterium (Gray 
et al., 1999). Over 2 billion years of co-evolution, many ancestral mitochondrial genes have transferred 
to the nucleus (Falkenberg et al., 2007; Calvo and Mootha, 2010; Wallace, 2012). What remains in 
the mitochondrial genome is distinctive for the striking asymmetry between the two complementary 
mtDNA strands in terms of nucleotide content and gene distribution (Andrews et al., 1999). The 
heavy (H) strand is guanine-rich (C/G = 0.4) and is the template from which most mitochondrial 
proteins (12 out of 13) are transcribed, whereas only one protein-coding gene, MT-ND6, is transcribed 
from the correspondingly cytosine-rich light (L) strand.
Mutations in the mitochondrial genome cause inherited disease (Chinnery, 1993), with a maternal 
inheritance pattern because only eggs contribute mitochondria to the zygote. The penetrance of 
inherited mitochondrial disease is determined stochastically by both the random assortment of 
mutated vs wild-type mitochondrial genomes during meiosis and random drift during the early cell 
divisions after fertilization. In cancer, the role of somatically acquired mtDNA mutations is contro-
versial. Although cancer-specific mutations have been previously reported (Polyak et al., 1998; 
Brandon et al., 2006; Chatterjee et al., 2006; He et al., 2010; Larman et al., 2012), the limited 
sample size or poor sensitivity of capillary sequencing for heteroplasmic mutations has not allowed 
a comprehensive analysis of the mutational signatures of mitochondrial mutations nor their likely 
functional significance. It has long been proposed that mitochondria might contribute to cancer devel-
opment given their fundamental importance to cellular biology (Wallace, 2012). Previous reports 
suggested that mitochondrial somatic mutations might be under positive selection and thus contribute 
to cancer development, but the small number of reported mutations renders this conclusion uncertain 
(Brandon et al., 2006; Chatterjee et al., 2006; Larman et al., 2012; Schon et al., 2012). Nonetheless, 
the hypothesis of functionally relevant mitochondrial mutations is an appealing one because cancer 
cells have greatly increased energy demands over normal cells and demonstrate a switch from aerobic 
glycolysis in mitochondria to lactic acid fermentation in the cytosol (the Warburg effect) (Hanahan and 
Weinberg, 2011; Koppenol et al., 2011).
In each cell cycle, the replicating genome is at risk of de novo mutations, which can promote the 
development of cancer. These mutations may be generated by intrinsic cellular errors during DNA 
replication or repair or through exposure to mutagens, such as reactive oxygen species, tobacco 
smoke, and ultraviolet light (Pleasance et al., 2010a, 2010b). Recently, >20 mutational signatures 
operative in cancers have been identified in the nuclear genome (Alexandrov et al., 2013). Whether 
any of these mutational processes also affect the mitochondrial genome has not been studied. 
Furthermore, whether there are mtDNA-specific mutational processes in somatic cells remain unclear, 
although the many unique features of mtDNA replication and repair, coupled with the high concentration 
of reactive oxygen species generated by the electron transport chain, could be associated with distinctive 
mutation signatures.
In this study, we compare 1675 cancer and paired normal mtDNA sequences across 31 tumor types 
using massively parallel DNA sequencing technologies to obtain a systematic and unbiased catalog of 
somatic mitochondrial mutations. We find that mtDNA mutations are almost exclusively the product of 
a mutational process that is specific to mitochondria and probably linked to the unique mechanism 
of genome replication these organelles employ. We find no evidence for positive selection of 
mitochondrial mutations during oncogenesis, suggesting that they confer no clonal advantage on the 
nascent cancer cells.
Results
mtDNA sequencing and Mutation Calling
We extracted the mtDNA sequences from 704 whole-genome and 971 whole-exome sequencing data 
generated on primary cancers and compared them with mtDNA sequences from their matched normal 
samples. Given the abundance of mtDNA per cancer cell, a standard coverage of 30–40× in the 
nuclear genome provides significantly greater coverage of the mitochondrial genome (average read 
depth = 7901.0×), enabling accurate identification of somatic mutations including rare heteroplasmic 
variants. We also assessed whether whole-exome sequencing could be used to identify mtDNA 
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mutations from off-target reads derived from the mitochondrial genome. We found an average read 
depth of 92.1× across the mitochondrial genome in exome studies. From 139 samples in which we 
had both exome and whole-genome sequencing data, the overall read depths correlated strongly 
(R2 = 0.59, Figure 1—figure supplement 1) as did variant allele fractions for mtDNA somatic mutations 
(R2 = 0.97, Figure 1—figure supplement 2). Validation experiments suggested the sensitivity of 
whole-exome sequencing for detection of mtDNA somatic mutations to be 71.4% compared to 
whole-genome sequencing (Figure 1—figure supplement 3 and ‘Materials and Methods’, ‘Off-target 
mtDNA reads in whole-exome sequencing’ and ‘DNA cross-contamination’).
To reduce potential false-positive calls of mtDNA somatic mutations, we only report variants called 
with an allele fraction of >3%. This eliminates the risk of miscalls due to mtDNA-derived pseudogenes 
in the nucleus (NuMTs) because mtDNA copy numbers are 100–1000 times higher than nuclear 
genomes in human somatic cells, and the sequence homology between mtDNA and NuMTs presented 
in the human reference genome is generally <95% (in 96 out of 101 NuMTs with length greater than 
300 bp). Furthermore, pairwise comparison between cancer and matched normal mtDNAs from the 
same individual further minimizes the contamination of NuMTs in the mutation calling.
The catalog of mtDNA somatic mutations
In total, 1675 tumor–normal pairs across 31 tumor types were analyzed (Table 1 and Supplementary 
file 1). For 61 of these patients, we had sequencing data available from multiple sites of the primary 
cancer, several time points or matched primary cancers, and metastases (a total of 73 such cancer 
samples), allowing us to study the timing of mtDNA mutations in cancer evolution (Supplementary 
file 1). We identified 1907 somatic mtDNA substitutions (Figure 1 and Supplementary file 2). In 
contrast to inherited polymorphisms (n = 38,706, available at Supplementary file 2), which were 
almost always homoplasmic in both the cancer and counterpart normal, the variant allele fractions 
(VAFs) of these somatic substitutions were highly variable in the cancer, ranging from our detection 
threshold (3%) to homoplasmy (100%). Of these 1907 somatic substitutions, 1209 (63.4%) were not 
registered in the databases of mtDNA common polymorphism (Ingman and Gyllensten, 2006; Levin 
et al., 2013). In comparison, when we examined substitutions found in both the tumor and the normal 
samples from a patient, only 21 (0.05%) were not registered in the polymorphism databases, a 
significantly different fraction from the tumor-only variants (p < 10−10; Chi-squared test). We found 
595 (31.2%) recurrent mutations that can be collapsed onto 246 mtDNA positions, which is a 6.9-fold 
higher level of recurrence than expected by chance (p < 10−10). This suggests that the generation 
or fixation of mtDNA mutations is not random, but influenced by factors such as the underlying 
mutational process or positive selection.
Of the 1675 cancer samples, 976 (58.3%) harbored at least one somatic substitution and 521 
(31.1%) had multiple substitutions, ranging from 2 to 7 (Figure 2A). In those with multiple substitu-
tions, 72 pairs of mutations were sufficiently close to phase (Nik-Zainal et al., 2012b) such that we 
could determine whether they were linked on the same mtDNA genome or were on different copies. 
We found that 45 (62.5%) pairs of mutations were linked on the same mtDNA genome (Supplementary 
file 3 and Figure 2—figure supplement 1). Furthermore, of these linked mutations, 33 showed a 
clear temporal order: that is, one mutation was demonstrably sub-clonal to the other. This is rather 
unexpected, since each somatic cell has 100–1000 copies of the mitochondrial genome, and we might 
anticipate that random mutations would, on average, affect different copies. That many pairs of 
mutations are phased on the same mtDNA genome and yet show a clear sub-clonal relationship 
suggests that they occur sufficiently separated in time to allow the mitochondrial genome carrying the 
earlier mutation to drift towards a substantial fraction of all genomes in that cell before the second 
mutation occurs, consistent with a previous report (De Alwis et al., 2009).
The number of somatic mtDNA substitutions varied significantly according to tumor type (p = 4.4 × 10−52) 
after correcting for confounding variables such as sequencing coverage: gastric, hepatocellular, 
prostate, and colorectal cancers had the highest number of mtDNA substitutions (Figure 2B). In 
contrast, hematologic cancers (acute lymphoblastic leukemia, myeloproliferative disease, and myelo-
dysplastic syndrome) had fewer mutations. Several possible explanations could underpin these differ-
ences across tumor types. It could be that the mutation rates differ across cell lineages; it could be that 
selection pressures shape the number of mutations; or the number of mtDNA genome generations 
could differ across cell lineages. Of these explanations, we believe that the second is unlikely because, 
as we shall see, positive selection is not a major component of mitochondrial mutations. Interestingly, 
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Figure 1. Mitochondrial somatic substitutions identified from 1675 Tumor–Normal pairs. mtDNA genes and intergenic regions are shown. The strand of 
genes is shown based on mtDNA strand containing equivalent sequences of transcribed RNA. Substitution categories (silent, non-silent (missense and 
nonsense), non-coding (tRNA and rRNA), and intergenic) are shown by the shapes of each substitution. Six classes of substitutions are presented 
color-coded. The substitutions on the H, and L strand (when six substitutional classes were considered) are shown outside and inside of mtDNA genes, 
respectively. Vertical axes for H and L strand substitutions represent the VAF of each variant.
DOI: 10.7554/eLife.02935.004
The following figure supplements are available for figure 1:
Figure supplement 1. Correlation in amount of mtDNA reads between whole-genome and whole-exome sequencing. 
DOI: 10.7554/eLife.02935.005
Figure supplement 2. Correlation of heteroplasmy levels between whole-genome and whole-exome sequencing. 
DOI: 10.7554/eLife.02935.006
Figure supplement 3. Validation of mtDNA somatic substitutions. 
DOI: 10.7554/eLife.02935.007
Figure supplement 4. Amount of off-target mtDNA reads across four sequencing centers. 
DOI: 10.7554/eLife.02935.008
Figure supplement 5. Filtering samples of potential DNA contaminations. 
DOI: 10.7554/eLife.02935.009
we find a positive correlation between the number of mtDNA somatic mutations and age at diagnosis 
in breast cancers (p = 0.0004; Figure 2C), in keeping with the idea that the number of mitochondrial 
generations is linked to mutation burden. The mutational burden of an established cancer represents 
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the accumulated variation acquired in the lineage of cell divisions from fertilized egg to transformed 
cell and will include events acquired in normal development and homeostasis as well as those acquired 
during tumorigenesis (Stratton et al., 2009). Interestingly, mtDNA mutations have been found at high 
Figure 2. mtDNA somatic substitutions of human cancer. (A) Number of somatic substitutions in a tumor sample. (B) Average number of somatic 
substitutions per sample across 31 tumor types. (C) Age of diagnosis and number of mtDNA somatic substitutions in breast cancers.
DOI: 10.7554/eLife.02935.010
The following figure supplement is available for figure 2:
Figure supplement 1. VAFs of phased somatic mtDNA substitutions. 
DOI: 10.7554/eLife.02935.011
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rates in normal colonic crypt cells (Taylor et al., 2003; Ericson et al., 2012). Given that we find high 
burdens of mutations in colonic tumors as well, the differences we see across tumor types may arise 
from pre- or post-transformation differences in mtDNA burden across tissues.
Extracting mtDNA mutational signatures
With respect to signatures of somatic substitutions, C > T and T > C transitions constituted 90.9% of 
all the 1907 substitutions (Figure 1) among the six classes of possible base substitutions. To charac-
terize this aggregated signature of mtDNA cancer specific mutations in more detail, we looked for the 
presence of mtDNA strand bias between the complementary H and L strands of mtDNA. The two main 
substitution classes showed an extreme level of mtDNA strand bias. 84.1% of the C > T transitions 
were on the H strand. This level of strand bias occurred despite the fact that cytosine is 2.4-fold less 
common on the H than the L strand, so the C > T substitution rate is 12.6-fold higher on the H strand. 
By contrast, 76.8% of the T > C transitions were on the L strand despite its lower thymine content (1.3-
fold less than the H strand). This implies that the T > C mutation rate on the L strand is 4.2-fold higher 
than on the H strand.
We then examined the sequence context in which these mutations occurred by examining the 
bases immediately 5′ and 3′ to the mutated bases. This generates 96 possible mutation classes (the 6 
substitution classes multiplied by the 16 combinations of immediate 5′ and 3′ nucleotides). Both C > T 
and T > C mutations showed highly distinctive sequence contexts. CH > TH substitutions (i.e. C > T 
mutations on the H strand) were enriched for the NpCpG trinucleotide context (8- to 15-fold more 
frequent than expected by chance; Figure 3A). By contrast, TL > CL substitutions (i.e. T > C mutations 
on the L strand) showed 5- to 8-fold enrichment in NpTpC. This strand-asymmetric mutational signa-
ture is not similar to any of the 21 cancer-associated mutational signatures recently identified from the 
nuclear DNA of 30 different cancer types (Alexandrov et al., 2013).
Of the 18 tumor types that presented at least 25 mtDNA somatic substitutions in this study, the mu-
tational signatures were broadly consistent across tumor types (Figure 3B), with the exception that 
multiple myeloma had a somewhat higher rate of TH > CH changes than other histologies (p = 8.1 × 10−6). 
Thus, in contrast to the mutational signatures found in nuclear genomes, where there is striking hetero-
geneity both across tumor types and across individuals within a tumor type (Alexandrov et al., 2013), 
the mutational profile in the mitochondrial genome of somatic cells is remarkably homogeneous.
Replication-coupled mutational process in mitochondria
The major known cause of mutational strand bias in nuclear DNA is transcription-coupled nucleotide 
excision repair, where DNA lesions on the transcribed (non-coding) strand are more frequently repaired 
(Alexandrov et al., 2013). However, we find that the strand bias always favors CH > TH and TL > CL 
whether the gene is transcribed from the H strand or from the L strand (Figure 3—figure supple-
ment 1). This is not compatible with transcription-coupled repair, for which the direction of strand 
bias is fundamentally dictated by which strand is transcribed.
Instead, the mtDNA mutational strand bias reported here appears to be driven by differences in 
replication between the two strands. mtDNA replication harbors substantial strand asymmetry 
between the H and L strands: mtDNA replication initiates from an origin of replication (OH) in the 
D-loop, with the nascent H and the L strand replicating as leading and lagging strand, respectively 
(Clayton, 1982; Falkenberg et al., 2007; Holt and Reyes, 2012). We observed that C > T substitu-
tions were prevalent in the leading (heavy) strand, whereas T > C substitutions were found in the lag-
ging (light) strand (Figure 1). Remarkably, this strand bias was reversed in the D-loop itself (Figures 1 
and 3C), further suggesting that the mtDNA somatic mutations are replication-coupled: according to 
a recently proposed bidirectional model of mtDNA replication (Yasukawa et al., 2005, 2006; Holt 
and Reyes, 2012), mtDNA replication is also able to initiate from the so-called Ori-b site, typically 
located around genomic position 16,197 and proceeds on both strands away from the origin (Figure 1). 
Replication of the nascent H strand continues unimpeded like the traditional model, but the nascent L 
strand terminates at the so-called OH site, typically around mtDNA position 191 bp. Under this model, 
then, the leading and lagging strand are reversed in the few hundred base-pairs of the D-loop, which 
is consistent with the reversed mutational signature in this region (Figures 1 and 3C).
Equivalent mutational signature during human mtDNA Evolution
It is not entirely straightforward to infer the mutational signatures operating on the mitochondrial 
genome in the germline. De novo mutations are generally rare and often discovered because they 
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Figure 3. Replicative strand bias for mtDNA somatic substitutions. (A) Replicative strand-specific substitution rate (# of observed/# of expected) by 96 
trinucleotide context. Substitutions in a specific mtDNA segment (from Ori-b to OH) are not included, because they present a different substitutional 
signature. (B) Mutational signature across tumor types. Eighteen tumor types, which include at least 25 mtDNA mutations, were shown. (C) Inverted 
substitution signature in the Ori-b–OH.
DOI: 10.7554/eLife.02935.012
The following figure supplement is available for figure 3:
Figure supplement 1. Replicative strand bias observed in mtDNA substitutions. 
DOI: 10.7554/eLife.02935.013
cause disease; distinguishing the ancestral base and the derived base is challenging for single nucleo-
tide polymorphisms; and comparative mtDNA genomics across species extends over considerable 
evolutionary time. In contrast, because ancestral and derived states are defined for tumor–normal 
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pairs, a much clearer picture emerges of the somatic mtDNA mutation signature. We therefore 
assessed whether the signature that emerges for somatic mitochondrial mutations could extend to 
explain sequence composition of the human mtDNA genome.
It appears that the mutational mechanism which has generated the CH > TH and TL > CL signature in 
cancer mtDNA is equivalent to the one that has been operating during evolution of human germline 
mtDNA (Nikolaou and Almirantis, 2006). This manifests as the depletion of certain codons in the 
reference human mtDNA sequence through the action of the CH > TH and TL > CL mutational process 
over time (Figure 4A). For example, the GCG triplet codon (Alanine) appears to have been replaced 
by its synonymous GCA codon (due to CH > TH (GL > AL)), with the former being 15.8-fold less 
frequently observed in the 12 mtDNA protein-coding genes that are transcribed from the H strand 
(and encoded on the L strand). All 32 synonymous codon pairs present the same tendency. Consistent 
with this interpretation, the gene transcribed from the L strand (MT-ND6) demonstrates the opposite 
direction of skew. Further analyses of mtDNA codon usage from seven animal species suggest that the 
CH > TH and TL > CL mutational pressure may be characteristic of vertebrates, and primates in particular 
(Figure 4—figure supplement 1).
To quantify whether the somatic mutational signature we have defined can fully explain the 
trinucleotide frequency of human mtDNA, we performed evolutionary simulations. First, we simulated 
the evolution of a random DNA sequence under the mutational signature described here. By 
mutational pressure alone, the random sequence starts losing certain hypermutable trinucleotides 
until eventually reaching a stationary sequence composition. The actual sequence composition of 
the human mitochondrial genome strongly resembles this stationary distribution (Pearson's r = 0.83; 
p < 0.0001; Figure 4—figure supplement 2). In a second simulation, a random sequence encoding 
the exact amino acid sequence of the reference mitochondrial genome was evolved by synonymous 
mutations under the observed mtDNA signature until reaching a stationary sequence composition 
(mutation–selection equilibrium). These simulations also eventually approximate the observed 
human mitochondrial genome (Pearson's r = 0.96, p < 0.0001; Figure 4B). These analyses strongly 
suggest that the mitochondrial mutation signature observed in cancer cells closely reflects the 
mutation signature active in the germline, which has continuously shaped the mitochondrial genome 
during human evolution.
Negative selection on truncating mtDNA mutations and tRNA 
anticodons
Next, we assessed the functional impact of somatic mtDNA mutations. Of the 1907 substitutions, 1153 
(60.5%) were in the 13 protein-coding genes. These include 63 nonsense, 4 stop-lost, 878 missense, 
and 208 silent substitutions (Supplementary file 2). In addition, out of 251 indels we observed, 110 
occurred within protein-coding genes (Supplementary file 2). Of the missense substitutions, 245 
(27.9%) were recurrent, affecting 107 distinct mtDNA sites. Although this very high level of mutation 
clustering could, at first sight, be interpreted as evidence for positive selection, we found that 
silent substitutions were also frequently recurrent (28 recurrent variants in 13 mtDNA sites), with no 
substantial difference in recurrence rates between silent and missense mutations (p = 0.19; Figure 5—
figure supplement 1). We believe this recurrence to be the consequence of a high mtDNA mutation 
rate with restricted mutational signature (CH > TH and TL > CL). Independently recurring mutations in 
human germline mtDNA are well described across human evolution (Levin et al., 2013).
The ratio of somatic missense to silent substitutions (Rms:s) is apparently higher (4.2, 878/208) than 
that observed for cancer-associated somatic mutations in nuclear DNA (generally around 2:1 to 3:1 
across tumor types) (Greenman et al., 2007; Nik-Zainal et al., 2012a). At face value, this again could 
be interpreted as evidence for positive selection. However, as described above, the somatic mtDNA 
mutational signature shows extreme strand asymmetry and the same mutational signature has been 
operative in the germline over evolutionary time. Thus, the dominant mutational signature has already 
acted on potentially synonymous sites in the mitochondrial genome (Figure 4A), meaning that any 
new somatic changes are much less likely to be silent. In keeping with this, a dN/dS ratio (See ‘Materials 
and Methods’) calculated taking into account both the mutational signature and the mtDNA codon 
usage revealed that missense mutations accumulate at a frequency very close to that expected under 
neutrality (dN/dS = 1.21; 95% confidence interval, 1.015–1.434; p = 0.031). This indicates that despite 
the apparent high ratio of missense to silent mutations, the vast majority of mtDNA mutations are 
passengers with no convincing evidence suggesting the existence of driver mitochondrial DNA 
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Figure 4. Mutational signature similar to processes shaping human mtDNA sequence over evolutionary time. (A) 
Triplet codon depletion in human mtDNA by equivalent (CH > TH and TL > CL) mutational pressure. Relative frequency 
of each triplet codon within synonymous pairs (NNT–NNC or NNA–NNG) is shown by color. The arrows beside  
the box highlight the T > C (red) and G > A (blue) substitutional pressures on the L strand in germline mtDNA.  
(B) Correlation of triplet codon frequencies between from observed and from simulated evolutions of a random 
sequence mtDNA by the mtDNA somatic mutational signature with constraining mitochondrial protein sequences.
DOI: 10.7554/eLife.02935.014
Figure 4. Continued on next page
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mutations. Additional gene-by-gene analysis further revealed that no single gene had a higher than 
expected rate of missense or nonsense mutations (Supplementary file 4).
For nonsense substitutions and frameshift indels, we observe a somewhat different picture. Taking 
into account the mutation signature and amino acid composition of the mitochondrial genome, the 
overall ratio of nonsense mutations to silent mutations is exactly that expected by chance (dNonsense/
dS = 1.004; 95% confidence interval, 0.699–1.443; p = 0.98). However, while missense and silent sub-
stitutions exhibited equivalent variant allele fractions (average VAFs; 40.1% and 40.9%, respectively; 
p = 0.8), nonsense substitutions presented significantly lower VAFs (average 26.4%; p = 6x10−5), as did 
frameshift indels (average 25.0%; p = 2 × 10−3; Figure 5A). Taken together, these data suggest that 
nonsense mutations occur at the expected rate given the underlying mutational process. However, 
while silent and missense substitutions frequently achieve high allele fractions in tumor cells due to the 
effects of random drift, there are significantly greater constraints on mitochondrial genomes carrying 
protein-inactivating mutations. The inference here is that cancer cells carrying such deleterious muta-
tions at or near homoplasmy are at a selective disadvantage and hence do not contribute to clonal 
expansions, underlining the importance of functional mitochondria to cancer cells. The extent of such 
disadvantage may vary according to tumor type: for example colorectal cancers show less negative 
selection compared to breast cancers (p = 0.028; Figure 5—figure supplement 2).
We found 171 mtDNA substitutions in mitochondrial tRNA sequences, which are very similar to the 
expected number (168.2, p = 0.82) from the mutational signature. Interestingly, none of the substitu-
tions was located in the trinucleotide anticodon site of the tRNA (expected number = 7.6, p = 0.006). 
This suggests that mutations in tRNA anticodons confer a similar selective disadvantage as protein-
truncating mutations, presumably because such mutations would lead to systematic erroneous ami-
noacylation of nascent proteins during translation of the relevant codon.
Next, we assessed whether any specific somatic mutations showed evidence of positive selection. 
Out of the 1907 somatic substitutions, 16 (0.8%) overlapped with known disease-associated mtDNA 
mutations, such as mutations frequently detected in MELAS (Mitochondrial Encephalomyopathy, lactic 
acidosis, and stroke-like episodes) and LHON (Leber hereditary optic neuropathy) (Supplementary 
file 2). In addition, ten mutations within mitochondrial protein-coding, tRNA and rRNA genes showed 
significantly higher recurrent rate than expected from background mutational signature (Supplementary 
file 5). However, it remains unclear whether this high recurrence reflects positive selection, because 
any factors not included in our background model of the mutational process, such as local mutation 
hotspots, could also explain a mild excess of mutations at a given nucleotide.
mtDNA mutations across tumor Evolution
We investigated whether somatic mtDNA mutations are more likely to become homoplasmic later in 
tumor evolution by assessing paired cancer samples, either primary and metastasis (breast, colorectal, 
and prostate) or primary and relapse (myeloma) (Figure 5B and Supplementary file 1). As mentioned 
earlier, 73 late (metastasis or relapse) cancer samples were sequenced in addition to the primary tis-
sues. Among the mtDNA mutations identified in either of the paired cancer samples, a number of 
different patterns were observed. There were mutations at high VAF in the primary not found in the 
metastasis (n = 49); mutations in the metastasis not found in the primary (n = 49); and shared mutations 
(n = 71) at high or low VAF, sometimes with evidence for drift (VAF difference >0.2) between the two 
samples (n = 25). These data, particularly the mutations found in the metastasis only, suggest that 
mitochondrial mutations can occur throughout the time course of tumor evolution, and still drift to 
homoplasmy with appreciable frequency, as suggested previously (Coller et al., 2001). To assess the 
plausibility of this conclusion, we modeled the dynamics of mtDNA mutations based on a few simplify-
ing assumptions (See ‘Materials and Methods’, Evolutionary dynamics of neutral mitochondrial 
The following figure supplements are available for figure 4:
Figure supplement 1. TC and GA skew for L strand mtDNA genes across 8 animal species. 
DOI: 10.7554/eLife.02935.015
Figure supplement 2. Correlation of triplet codon frequencies between from observed and from simulated 
evolutions under the mtDNA somatic mutational signature. 
DOI: 10.7554/eLife.02935.016
Figure 4. Continued
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mutations). We find that the expected number of neutral mitochondrial mutations drifting to homo-
plasmy increases linearly with mutation rate and number of cell divisions. Based on a mutation rate of 
10−7/base-pair/generation (Coller et al., 2001; Hudson and Chinnery, 2006), this leads to an average ∼1 
homoplasmic mutation for every 1000 cell generations.
Figure 5. Selection and mutational process for mtDNA somatic substitutions. (A) Truncating mutations (nonsense substitutions and frame-shifting (FS) 
coding indels) present significantly lower VAF. (B) Change of VAF of mtDNA somatic mutation between primary and metastatic (or late) cancer tissues. 
(C) Mutational signature for mtDNA across various tumor types. None of the three highlighted mechanisms or nuclear DNA double-strand breaks repair 
mechanism (BRCA) match with the mtDNA mutational signature. * Only substitutions in protein-coding genes considered. (D) A proposed model of 
mtDNA mutational process.
DOI: 10.7554/eLife.02935.017
The following figure supplements are available for figure 5:
Figure supplement 1. Number of recurrent substitutions between silent and missense substitutions. 
DOI: 10.7554/eLife.02935.018
Figure supplement 2. Comparison of VAF of protein-truncating mutations (nonsense substitution and indels) across tumor types. 
DOI: 10.7554/eLife.02935.019
Figure supplement 3. Negligible impacts of external mutagens (UV and tobacco smoking) to the somatic mtDNA mutations. 
DOI: 10.7554/eLife.02935.020
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Origins of mtDNA somatic mutations
We also explored whether the mutational forces that are so critical to shaping the nuclear genome 
during tumor evolution could affect the mitochondrial genome. In cancers associated with exogenous 
mutagens, such as tobacco-associated lung cancer and ultraviolet light-associated melanomas, we 
found no evidence of the mutational signatures characteristic of these carcinogens among the mtDNA 
mutations (Figure 5C, Figure 5—figure supplement 3). Moreover, BRCA1 and BRCA2 mutations 
showed no evident influence on mitochondrial genomes in breast cancer (Figure 5C), in contrast to 
their effects on nuclear genomes exhibiting an even distribution of mutations across all trinucleotide 
contexts (Nik-Zainal et al., 2012a; Alexandrov et al., 2013). Taken together, it appears that the primary 
mtDNA mutational process is endogenous to mitochondria and is very different to those operating in 
nuclear DNA. It is surprising that the endogenous mutational process has far greater impact than any 
external forces, as the physicochemical interactions of ultraviolet light or the chemicals in cigarette 
smoke with DNA should be similar in both genomes. The simulations described above suggest the 
major explanation to be that the endogenous mutation rate is several orders of magnitude greater 
than that expected for exogenous carcinogens, thus swamping any signal.
Discussion
In theory, there are two potential sources of the mtDNA variants we observed in cancer tissues: 
(1) somatically acquired, or de novo, mutations accumulated during the cancer clone's lineage of cell 
divisions from the fertilized egg or (2) low-level heteroplasmic mtDNA present in the oocyte (therefore 
maternally inherited) amplified in cancer but lost from normal tissue by random drift (He et al., 2010; 
Freyer et al., 2012; Payne et al., 2013). We believe the majority of the variants we find are genuinely 
acquired somatically. First, of the 45 pairs of somatic mutations phased together on the same copy of the 
mtDNA genome, at least 33 (73.3%) showed a clear sub-clonal relationship and therefore their occur-
rence is separated in time, or apparently somatic. Secondly, 63.4% of our substitutions were not pre-
viously reported as germline polymorphisms. This is a much higher rate than reported for equivalent 
analyses on heteroplasmic variants in non-cancer samples (8/37; 21.6%) (Li et al., 2010), although meth-
odological differences may somewhat contribute to this apparent difference (Goto et al., 2011; Avital 
et al., 2012). Thirdly, if the variants were due to inherited low-level heteroplasmy, we would not expect 
to see such variation across tissue types, since all tissue types derive from the fertilized egg. It is difficult 
to distinguish whether the variants we observe occur before or after the initiating driver mutations that 
herald tumorigenesis, but our analysis of paired samples does suggest that they can occur both early 
and late. Given the homogeneity of the mutational signature across tumor types and its inferred resem-
blance to the germline mtDNA mutational process, we would hypothesize that new mutations occur 
at a fairly constant and high rate per mitochondrial genome replication throughout all cell divisions.
On the basis of the mutational signature observed here, somatic substitutions are unlikely to be 
attributable to reactive oxygen species (ROS), as previous reports have suggested (Polyak et al., 1998; 
Larman et al., 2012). Guanine oxidation by ROS predominantly causes G:C > T:A transversion (Thilly, 
2003; Delaney et al., 2012), which constitute only 4.0% of the mutations in our data (Figure 5C). 
Instead, we propose three replication-coupled mechanisms that can explain the strand asymmetric 
CH > TH and TL > CL mutational signature and define a model of the mtDNA mutational process 
(Figure 5D). First, the parent H strand, displaced and single-stranded during mtDNA replication (Holt 
and Reyes, 2012), could be more prone to cytosine deamination (generating CH > TH) and/or adenine 
deamination (Lindahl, 1993; Saccone et al., 1999; Faith and Pollock, 2003) (generating TL > CL). 
Secondly, endogenous mtDNA polymerase (POLG) replication errors (Zheng et al., 2006) (which show 
the pattern of C > T and A > G substitutions) could be preferentially generated on the leading strand 
(Pavlov et al., 2002). Thirdly, there may be differences between the efficiency of repair between 
the leading and lagging strand (Pavlov et al., 2003). Further, the mutation pattern reported here is 
consistent with the hypothesized bidirectional initiation of mtDNA genome replication (Yasukawa 
et al., 2005, 2006; Holt and Reyes, 2012).
It appears that most of the mtDNA missense mutations we observe become fixed in tumor progenitor 
cells without distinct physiological advantage. All the statistical testing performed in this study—
variant allele fraction comparison across different categories of somatic mutations, number of recurrent 
mutations, and dN/dS ratio—suggest that mtDNA somatic substitutions accumulate largely neutrally. 
This is not different from previous observations in nuclear genomes: of the thousands of somatic 
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mutations found in a cancer genome, many fewer than a hundred are believed to confer a selec-
tive advantage to the cancer cell (Stratton et al., 2009). In contrast, protein-truncating mutations 
showed evidence of negative selection, at the level of constraints on the allele fraction achieved. The 
implication of this is that the inactivating mutations occur at an appreciable rate, but the fraction of 
mitochondrial genomes per cell carrying these variants cannot increase beyond a certain limit without 
impairing the selective fitness of that cell. Having a sizable number of mitochondria with fully intact 
proteome remains critical to the fitness of a cancer cell.
Materials and methods
Sequencing data
All the sequences were generated by Illumina platforms (either Genome Analyzer or HiSeq 2000). With 
respect to TCGA data, we downloaded aligned bam files through UCSC CGHub (http://cghub.ucsc.
edu). Sequencing reads were aligned on the human reference genome build 37 (GRCh37) and human 
reference mtDNA sequence (revised Cambridge reference sequence, rCRS [Andrews et al., 1999]), 
mainly by BWA alignment tool. Samtools (Li and Durbin, 2009) and Varscan2 (Koboldt et al., 2012) 
were used for manipulating sequence reads and for calling somatic mutations, respectively. Sequence 
data have been deposited in the European Genome-phenome Archive (EGA; https://www.ebi.ac.uk/
ega/home ; study accession # EGAS00001000968; dataset accession numbers EGAD00001001014 for 
primary samples and EGAD00001001015 for metastatic samples). Sample accession numbers are 
available in the Supplementary file 6.
Off-target mtDNA reads in whole-exome sequencing
Most of the currently available whole-exome capture kits, including Agilent Technologies SureSelect 
Human All Exon 50 Mb (Agilent Technologies Inc., Santa Clara, CA) used mostly in this study, do not 
target mtDNA genes (Falk et al., 2012). However, because of the abundance of mtDNA in human cells 
(100–100,000 copies per cell), it is expected that a number of mtDNA fragments could be off-target 
captured. We checked whether the amount of off-target mtDNA reads was sufficient for mtDNA 
variant detection. Whole-exome sequencing (normal samples) generated by CGP (n = 855), WUGSC 
(Washington University Genome Sequencing Center; n = 140), and BCM (Baylor College of Medicine; 
n = 85) contained ∼100 off-target mtDNA reads per 1M autosomal reads (Figure 1—figure supple-
ment 4). We concluded that these could be sufficient for the downstream analyses, because ordinary 
10 Gb whole-exome data would provide ∼60× read depth for mtDNA here. However, whole-exome 
data sequenced by BI (Broad Institute; n = 436) included far less, ∼3 off-target mtDNA per 1 M auto-
somal reads, which would show ∼2× mtDNA read depth per 10 Gb exome sequencing (Figure 1—
figure supplement 4). It may be due to ‘improved’ exome-capture protocols by BI to increase the 
DNA-capture efficiency and on-target rate (Fisher et al., 2011). Therefore, we did not include whole-
exome data sequenced from BI for further analysis.
139 samples were sequenced by both whole-genome and whole-exome sequencing. From these, 
we compared the amount of off-target mtDNA reads from whole-exome sequencing with that of 
whole-genome sequencing. It showed clear positive linear correlation (Figure 1—figure supplement 1).
DNA cross-contamination
Given the abundance of mtDNA in the cancer cells, 1–214× coverage cancer whole nuclear genome 
sequencing provides extensive coverage of mtDNA (average read depth = 7901.0×; Supplementary 
file 2) enabling accurate identification of somatic mutations, even if heteroplasmic. Whole-exome 
sequencing data were also included because off-target reads provided sufficient coverage (average 
read depth = 92.1×) to analyze mtDNA mutations.
This high coverage of mtDNA, especially from whole-genome sequencing, permitted us to identify 
heteroplasmic variants (our detection threshold was 3%; see ‘Variant calling’ for more details). However, 
because sample swaps and/or DNA cross-contaminations would definitely generate false-positive so-
matic variants, we filtered out suspicious DNA samples as described below.
 
1. Major sample swaps
A subset of tumor and normal sequencing pairs, of which the nuclear genotypes were not 
matching with each other, were removed from further analyses. We randomly selected 320 
common single-nucleotide polymorphism sites on the 22 human autosomes, of which the minor 
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allele frequency is ∼50% (45–55%) according to The 1000 Genomes Project (1000 Genomes 
Project Consortium et al., 2010). Of the 320 sites, homozygous positions in normal tissues 
(which showed >90% variant allele fraction (VAF) with bases Q score >20) were compared  
with the corresponding genotypes in the counterpart cancer. Sample pairs were removed if the 
genotype mismatch rate was greater than 0.1 (
Nhet Nwt
Nhom Nhet Nwt
+
+ + ; Nhet, number of heterozygote 
positions; Nhom, number of homozygote positions; Nwt, number of wild-type positions) 
(Figure 1—figure supplement 5A). We note 0 is expected for the rate when genotyping is 
perfect and sample pairs are from the same individual. By contrast, 0.5 is expected when 
samples were from different individuals.
2. Minor cross-contamination
We estimated DNA cross-contamination levels with the VAF of autosomal homozygous SNPs 
genotyped from the common (population minor allele frequency ∼50%) SNP sites. Theoretically, 
if there is no sequencing (and mapping) error, all the homozygote SNP sites in pure samples 
should present 100% VAFs. However, when samples are contaminated, corresponding VAFs are 
reduced because the contaminant has only an ∼25% of chance of having homozygote SNPs on 
the same site. Therefore, minor contamination levels (C) of each cancer sequencing data were 
estimated as below:
∑
∑
RCwt Ne
C
RDhom Ne
= × ( ) –2 ,
( ) –  
where RDhom is sequencing read depth, RCwt is read-count of wild-type alleles, and Ne is number 
of sequencing errors on each autosomal homozygote SNP site. For high accuracy, we only 
counted base with sufficient quality score (Q > 20). In order to estimate Ne, we assumed a  
conservative rate (sequencing error rate = 0.001). We considered sites covered by at least  
10 reads and 90% VAF (Figure 1—figure supplement 5B). 95% confidence intervals of cross- 
contamination levels were calculated using binomial distribution.
In order to clear somatic variants, here we made the very conservative assumption that somatic 
variants present in excess of 5-times of the 95% upper limit of C levels were true somatic rather 
than false-positives by low-level of cross-contamination.
3. Germline polymorphisms and back mutations
We further checked samples for contamination using known mtDNA polymorphisms. Because 
human mtDNA is small (16,569 bp) and extensively explored previously, most of germline 
mtDNA polymorphisms are already known. For example, 97.7% of the 39,036 inherited substitu-
tions were known polymorphisms in the mtDB database (Ingman and Gyllensten, 2006). 
Therefore, when a tumor sample is contaminated by other samples, many somatic-like mtDNA 
substitutions by contaminants are likely to be overlapped with known mtDNA polymorphisms.
At the same time, low-level contamination would generate excessive back mutations, which 
appeared to reverse germline common polymorphisms into wild-type alleles. Taken together, 
both the number of somatic substitutions known in mtDB and number of back mutations can be 
good indicators for mtDNA cross-contamination. Therefore, we filtered out tumor tissues with 
≥3 known potentially somatic mutations or with ≥2 back mutations from the further analyses 
(Figure 1—figure supplement 5A and B).
 
Variant calling
We extracted mtDNA reads using Samtools (Li and Durbin, 2009). We used VarScan2 (Koboldt et al., 
2012) for initial variant calling with a few options (--strand-filter 1 (mismatches should be reported by both 
forward and reverse reads), --min-var-freq 0.03 (minimum VAF 3%), --min-avg-qual 20 (minimum base 
quality 20), --min-coverage 3 and --min-reads2 2). With respect to the --strand-filter, it generally removes 
variant when >90% of mismatches are reported from either of the H or the L mtDNA strand. However, 
where only reads with a specific orientation are could be aligned dominantly (i.e. in both extreme 
region of mitochondrial reference genome; only L strand reads could be aligned on the 5′ extreme of 
mtDNA), we compared strand bias between ‘perfect matches’ (# perfect matches from L strand 
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reads / total # perfect matches) and mismatches (# mismatches from L strand reads / total # mismatches). 
If the difference between those two bias <0.1, the mutations were rescued. Of the 1907 mutations, 
54 (2.8%) were rescued accordingly.
Putative somatic variants called by VarScan2 were further filtered using criteria shown below.
 
1. At least 4 unique reads supporting variants and all variant reads at least 20 phred scale sequencing 
quality score (Q 20 = 1% sequencing error rate) and at least 3% variant allele fractions (VAFs).
 
A.  Regardless of in WGS and in WES, the ≥4 mismatches and the ≥3% VAF criteria must be satis-
fied simultaneously.
B.  However, in WGS, the minimum number of reads (n = 4) criterion is not essential, because the 
≥3% VAF criterion is much more stringent (3% VAF request at least 240 mismatches (>>4) 
given mtDNA coverage is ∼8000 for WGS).
C.  In WES, the ≥3% VAF criterion is relatively less important than in WGS, because the ≥4 mis-
matches criterion is more stringent. For example, 4 mismatches in 90x (WXS average) cover-
age region (VAF = 4.4%) automatically fulfill the ≥3% VAF criterion. For less covered regions 
(i.e. <40x coverage; n = 285 out of total 1907 substitutions), the VAF criterion becomes less 
important, because 4 mismatches would generate ≥10% VAF, much higher than the minimum 
threshold (i.e. 3%). As results, we are missing lower heteroplasmic variants (i.e. variants with 
3–10% heteroplasmic levels) from low coverage samples (mostly by WXS). The lower sensitivity 
of WXS is also confirmed in our validation study (see “Validation of somatic variants” below).
 
2. There is no minimum threshold for total coverage (# perfect matches + # mismatches).
3. To increase sensitivity for detecting mutations, we rescued mutations with 3 unique variant reads 
(with at least 20 phred scale sequencing quality score) when VAFs is ≥ 20%. Of 1907 somatic sub-
stitutions, 32 (1.7%) were rescued accordingly.
4. All somatic variants presenting with VAFs lower than our very conservative threshold for minor 
cross-contamination (5-times 95% upper limit of contamination levels for each tumor sample, see 
above “Minor cross-contamination of DNA samples”) were removed. When we could not estimate 
cross-contamination levels because of low sequencing depth of coverage (for nuclear genome), a 
conservative criterion (10% contamination level threshold) was explicitly used.
5. Substitutions were further visually inspected using IGV (Thorvaldsdottir et al., 2013). Thirteen 
frequent false-positive variants (shown below) by misalignment due to extensive level of homopoly-
mers in rCRS and due to sequencing error in the reference mtDNA genome (3107N, see Mitomap 
(http://www.mitomap.org/bin/view.pl/MITOMAP/CambridgeReanalysis) for more information) 
were explicitly removed:
 
1. Misalignment due to ACCCCCCCTCCCCC (rCRS 302-315)
A302C, C309T, C311T, C312T, C313T, G316C
2. Misalignment due to GCACACACACACC (rCRS 513-525)
C514A, A515G, A523C, C524G
3. Misalignment due to 3107N in rCRS (ACNTT, rCRS 3105-3109)
C3106A, T3109C, C3110A
 
 
We compared our variant calls with common inherited mtDNA polymorphisms deposited in the mtDB 
database as of 24th July 2013 (Ingman and Gyllensten, 2006). Gene annotation of somatic variants 
was done using custom script based on human mtDNA gene information (Ruiz-Pesini et al., 2007).
Validation of somatic variants
To validate the sensitivity and specificity of variant calling in this study, 19 tumor and normal pairs (which 
were originally whole-genome sequenced) were whole-exome sequenced and mtDNA variants were 
assessed independently. Among the 28 somatic substitutions originally detected from the 19 tumor–
normal whole-genome sequencing pairs, 20 (71.4%) were called as somatic (Figure 1—figure supple-
ment 3). In addition, 5 (17.9%) presented evidence of variant reads in the validation set, although it 
was filtered out because of its low read depth of coverage in exome sequencings (showed 2–5 variant 
reads). Moreover, because 3 remaining sites were not sufficiently covered in the validation set to call 
somatic variants, these could not be evidence of the inaccuracy of whole-genome sequencing data, 
therefore not considered in the accuracy validation. Taken together, all the 25 somatic substitutions by 
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whole-genome sequencing were highly likely to be true positives, therefore we concluded it provided 
∼100% accuracy in the mtDNA somatic substitution assessment. Actually, the high accuracy of whole-
genome sequencing is very likely and what we expect, because it provides extensive coverage of 
mtDNA (average read depth >7,500×), ∼3% heteroplasmic variants would present >200 variant reads.
By contrast, the validation set (whole-exome sequencing) is called 21 somatic substitutions. Of 
these, 20 were common with whole-genome sequencing, and one was incorrectly called as somatic 
though it was actually germline substitutions in the whole-genome sequencing data. In addition, as 
mentioned above, the validation set missed 8 somatic substitutions called by whole-genome sequencing. 
Six out of eight undercalls (75%) were low heteroplasmic substitutions in whole-genome sequencing, 
ranging from 3.36% to 8.68%. Based on these data, we suggest 71.4% sensitivity (20/28) and 
95.2% specificity (20/21) for exome-sequencing in detecting upto 3% heteroplasmic somatic mtDNA 
substitutions in cancer.
We further checked the correlation of heteroplasmy level between the 20 mtDNA somatic mutations 
called both whole-genome and whole-exome sequencing. It showed great linear relationship (R2 = 0.97, 
Figure 1—figure supplement 2), further suggesting whole-exome sequencing data are appropriate 
for accurate detection of mtDNA somatic mutations.
Substitution phasing
We phased 72 somatic substitution pairs, which arose in a single cancer sample and which located 
sufficiently close (from 10 bp to ∼500 bp), therefore both sites could be sequenced by same sequence 
fragments (Supplementary file 3 and Figure 2—figure supplement 1). We classified them as 
‘different strand’, ‘co-clonal’, and ‘sub-clonal’ using criteria as follows:
Different strand: the two somatic substitutions are obligate on different strands. Reads that report 
wild-type1(wt)-substitution2(subs) and subs1-wt2, but subs1-subs2, are observed.
Co-clonal: reads reporting wt1-wt2 and subs1-subs2 are only observed.
Sub-clonal: One substitution is sub-clonal to the other, but the two are definitely phased. Reads 
subs1-subs2 and either subs1-wt2 or wt1-subs2 are observed.
Tumor type and mtDNA somatic substitutions
To understand the relationship between tumor types and number of mtDNA mutations, Poisson re-
gression and ANOVA were applied to our dataset using R software (http://www.r-project.org).
         sub T NFit1 < - glm(N Cov + Cov , family = poisson())~  
           sub T NFit2 < glm(N Cov + Cov + t, family = poisson())- ~  
   anova(Fit1, Fit2, test = Chisq ),“ ”  
where Nsub is number of mtDNA substitutions of each sample, CovT and CovN are coverage of tumor 
and normal mtDNA, respectively, (if Cov is >200, we replaced it by 200), t is tumor types.
Age and mtDNA somatic substitutions
Poisson regression was applied to our breast cancer dataset.
          sub T NFit1 < glm(N Cov + Cov + a, family = poisson()),- ~  
where Nsub is number of mtDNA substitutions of each sample, CovT and CovN are coverage of tumor 
and normal mtDNA, respectively, (if Cov is >200, we replaced it by 200), a is age at diagnosis. p-value 
in estimation of a was shown in the manuscript.
Mutational signature and strand bias
Different mutational processes generate different combinations of mutation types, termed ‘signatures’ 
(Nik-Zainal et al., 2012a). For example, ultraviolet (UV) light and tobacco smoking (polycyclic aromatic 
hydrocarbons) frequently generate C > T transitions and G > T transversions on non-transcribed 
(coding) strands in melanoma and lung cancers, respectively (Pleasance et al., 2010a, 2010b). 
To understand the mutational processes influencing cancer mtDNA, we correlated the 1907 mtDNA 
substitutions with 21 cancer specific mutational signatures in the nuclear DNA recently identified 
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(Alexandrov et al., 2013). However, none of the signature could explain the highly unique mtDNA 
substitutions.
Mutational signature and strand bias were assessed as described in our previous reports (Alexandrov 
et al., 2013). Briefly, the immediate 5′ and 3′ sequence context was extracted from rCRS. Substitution 
rate for each trinucleotide context was calculated with the number of substitution normalized by 
the frequency of the trinucleotide context observed in the rCRS, in the L and H strand, respectively. 
For analyses of substitutions falling in the mtDNA genes (13 protein-coding and 22 tRNA genes), 
transcribed/non-transcribed strand was also considered for comparison.
In order to prove the strand bias is not transcription but replication-coupled, we checked strand 
biases of polymorphisms in the 12 L strand protein-coding genes, 1 H strand protein-coding gene 
(MT-ND6), and/or 22 tRNAs (Figure 3—figure supplement 1). For this specific purpose, we did not 
consider the sequence context (immediate 5′ and 3′ bases) because it over-classifies mutations 
(i.e. the number of mutation classes (n = 96) is larger than that of mutations). In other words, 12 classes 
of substitutions (six classes of possible base substitutions (C > A, C > G, C > T, T > A, T > C, T > G) × 
two strands (L and H strands)) were considered. Substitution rates are ratio between observed and 
expected numbers (H0 = same mutation rate for all substitution classes) for each substitution class. 
In order to understand which model (replicative or transcriptional strand) is appropriate to explain the 
strand-bias, Chi-square tests were used between the number of observed mutations for each class and 
expected ones under the background signature.
mtDNA codon usage
We counted the codon frequencies in 13 mtDNA protein-coding genes. Because 12 L strand protein-
coding genes and 1 H strand gene (MT-ND6) are under opposite mutational pressure (T > C and G > 
A for L strand genes; A > G and C > T for MT-ND6), we separated L and H strand genes for this 
analysis. T > C skew and G > A skew were calculated as shown below, to understand the TL > CL and 
CH > TH (equivalent to GL > AL) substitutions during the evolution of human mtDNA:
C T A G
skew skew
C T A G
– –
T C = G A = ,
+ +
N N N N
and
N N N N
> >
 
where NA, NC, NG, and NT are number of A, C, G, and T base in the 3rd position of triplet codons in 
mtDNA genes, respectively.
For the assessment of mtDNA codon usage of other animal species, we analyzed the mtDNA 
sequence of Caenorhabditis elegans (accession# NC_001328), Drosophila melanogaster (accession# 
NC_001709), D. rerio (accession# NC_002333), Xenopus laevis (accession# NC_001573), Mus musculus 
(accession# EU450583), Gallus domesticus (accession # NC_235570), and Pan troglodytes (NC_001643). 
We considered only L strand mtDNA genes in the cross-species analysis.
Recurrent substitutions
To compare the number of recurrent substitutions between silent and missense substitutions, we 
randomly selected 100 substitutions each from 198 silent substitutions in the third base of triplet 
codons, 440 missense substitutions in the first base of triplet codons, and 405 missense substitutions 
in the second base of triplet codons. We counted the number of recurrent substitutions in each group. 
This was iterated 300 times independently. ANOVA testing was applied to determine the difference 
between the three groups (Figure 5—figure supplement 1).
dN/dS ratio
To estimate dN/dS values for missense mutations (wmis), we used an adaptation of the method 
described previously (Greenman et al., 2006). Briefly, the rate of mutations is modeled as a Poisson 
process, with a rate given by a product of the mutation rate and the impact of selection. To obtain 
accurate estimates of dN/dS, we used two separate models, one using 12 single-nucleotide substitution 
rates and a more complex one accounting for any context dependence effect by 1-nucleotide upstream 
and downstream using 192 substitution rates. For example in the 12-rate model, the expected number 
of A > C mutations (λA>C) would be modeled as follows:
    
syn,A C A C syn,A C
= r L> > >λ *  
      
mis,A C A C mis mis,A C
= r w L ,> > >λ * *  
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where Lsyn,A>C and Lmis,A>C are the number of sites that can suffer a synonymous and missense A > C 
mutation, respectively, which are calculated for any particular sequence. The likelihood of observing 
the number of missense A > C mutations (Nmis,A>C) given the expected λmis,A>C is then calculated as:
  
mis,A C A C mis
Lik = Poisson(N r ,w )> > |  
and the likelihood of the entire model is the product of all individual likelihoods. Wmis is fixed to be 
equal in all 12 (or 192) equations describing each substitution type, and a hill-climbing algorithm is 
used to find the maximum likelihood estimates for all rate and selection parameters. Likelihood Ratio 
Tests are then used to test deviations from neutrality (wmis = 1). The dN/dS ratio reported in the main 
text corresponds to the full context dependent model with 192 substitution rates. This method allows 
quantifying the strength of selection avoiding the confounding effect of gene length, sequence com-
position, different rates of each substitution type, and context-dependent mutagenesis.
Short indels
Along with the 1907 somatic mtDNA substitutions, we identified 109 and 142 somatic short insertions 
and deletions, respectively, from the 1675 cancer mtDNA sequences using Varscan2 (Supplementary 
file 2).
Evolutionary dynamics of neutral mitochondrial mutations
We model the evolutionary dynamics of mitochondrial mutations under random drift and derive a 
simple equation for the expected number of homoplasmic mutations. There exist multiple levels at 
which mitochondrial mutations evolve: within mitochondria, in the cytoplasm, and on the cellular 
level (Rand, 2011). In this study, we focus on the dynamics in a single cell, which represents the 
founder of the last clonal expansion in the tumor cell population. The cellular dynamics during a 
clonal expansion is difficult to describe analytically, but it is important to realize that mutations of a 
clonal expansion preserves the allele frequencies of neutral variants and that mutations that occur 
after the expansion are unlikely to contribute to measurable allele frequencies, as the population 
becomes large.
We model the evolutionary dynamics of mitochondrial mutations in the cytoplasm of a single cell 
by a Wright–Fisher process (Wright, 1931), in which the number of mitochondria in a subsequent 
generation is a binomial sample of the mitochondria in the previous generation. The number of 
mitochondria M is kept fixed. The marginal allele frequency X of a single site has two absorbing 
boundaries, X = 0 and X = M (homoplasmy), and the probability of fixation of an allele at frequency 
X by neutral drift is ρ = X/M (Wright, 1931). Note that this process leads, on the population level, 
to a dichotomization of heteroplasmic variants to either go extinct or become homoplasmic and fixate 
in a cell.
Mutations on any of L (= 16,569 nt) sites in the mitochondrial genome are assumed to occur at a 
uniform rate μ per nucleotide per cell division, which is of order 10−7, based on a human inter-generational 
comparison (Coller et al., 2001). Hence the rate of neutral evolution is simply μLM/M = μL (Kimura, 
1984). Lastly, the expected time to fixation in the Wright–Fisher process is t = 2M. Putting these things 
together, the expected number of mutant alleles N in a cell initially without any mitochondrial muta-
tions after T generation is
   E[ ] =   ( – )N L T 2Mµ  
This equation predicts a linear accumulation of neutral mutations over time, with a delay imposed 
by number of mitochondrial copies. A similar behavior has been reported using numerical simulations 
(Coller et al., 2001). When also considering heteroplasmic mutations, the expected number of alterations 
may be slightly higher.
To check whether our model yields the correct behavior, we use the following numbers: the 
observed order of magnitude of mitochondrial mutations per patient was N = 1. The sequencing cov-
erage on the mitochondrial genome indicates that there were of order M = 100 mitochondrial genome 
copies present per cancer cell. The expected number of mutations per cell division is μL = 1.6 × 10−3, 
it therefore requires around 1000 cell generations T to accumulate on average one homoplasmic 
mutation. This number of generations appears realistic for regenerating tissues. As expected, epithelial 
cancers had among the highest observed number of mitochondrial mutations, while hematopoietic 
cancers typically had lower numbers.
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Statistical testing
Statistical testing was performed using R software. All p-values were calculated by two-tailed testing. 
Figures were generated using R and Microsoft Excel software.
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